Today, the CEO of Adamas Pharmaceuticals (ADMS), Gregory Went, bought shares of ADMS for $49.93K.
This recent transaction increases Gregory Went’s holding in the company by 1.02% to a total of $4.96 million.
See today’s analyst top recommended stocks >>
Based on Adamas Pharmaceuticals’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $10.61 million and GAAP net loss of $33.15 million. In comparison, last year the company earned revenue of $1,000 and had a GAAP net loss of $23.36 million. Currently, Adamas Pharmaceuticals has an average volume of 989.8K.
Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $28.25, reflecting a 117.3% upside. Three different firms, including Mizuho Securities and H.C. Wainwright, currently also have a Buy rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products includes ADS-5012, ADS-4101, and Namenda XR. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson’s disease.
